NYXOAH SA (NYXH.BR) Stock Fundamental Analysis
Europe - Euronext Brussels - EBR:NYXH - BE0974358906 - Common Stock
4.1 EUR
0 (0%)
Overall NYXH gets a fundamental rating of 2 out of 10. We evaluated NYXH against 67 industry peers in the Health Care Equipment & Supplies industry. NYXH has a bad profitability rating. Also its financial health evaluation is rather negative. NYXH is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year NYXH has reported negative net income.
- NYXH had a negative operating cash flow in the past year.
- In the past 5 years NYXH always reported negative net income.
- In the past 5 years NYXH always reported negative operating cash flow.
1.2 Ratios
- NYXH has a Return On Assets of -89.29%. This is amonst the worse of the industry: NYXH underperforms 91.04% of its industry peers.
- NYXH has a Return On Equity of -164.01%. This is amonst the worse of the industry: NYXH underperforms 85.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -89.29% | ||
| ROE | -164.01% | ||
| ROIC | N/A |
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 64.36%, NYXH is in the better half of the industry, outperforming 65.67% of the companies in the same industry.
- In the last couple of years the Gross Margin of NYXH has remained more or less at the same level.
- NYXH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
- NYXH has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for NYXH has been increased compared to 5 years ago.
- NYXH has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -4.21, we must say that NYXH is in the distress zone and has some risk of bankruptcy.
- NYXH has a worse Altman-Z score (-4.21) than 83.58% of its industry peers.
- NYXH has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
- NYXH has a Debt to Equity ratio (0.40) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.21 |
ROIC/WACCN/A
WACC7.43%
2.3 Liquidity
- A Current Ratio of 1.70 indicates that NYXH should not have too much problems paying its short term obligations.
- NYXH's Current ratio of 1.70 is in line compared to the rest of the industry. NYXH outperforms 53.73% of its industry peers.
- A Quick Ratio of 1.41 indicates that NYXH should not have too much problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 1.41, NYXH is in the better half of the industry, outperforming 73.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.41 |
3. Growth
3.1 Past
- The earnings per share for NYXH have decreased strongly by -30.42% in the last year.
- Looking at the last year, NYXH shows a quite strong growth in Revenue. The Revenue has grown by 10.96% in the last year.
- Measured over the past years, NYXH shows a very strong growth in Revenue. The Revenue has been growing by 74.42% on average per year.
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.02%
Revenue 1Y (TTM)10.96%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%55.77%
3.2 Future
- NYXH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.64% yearly.
- The Revenue is expected to grow by 117.81% on average over the next years. This is a very strong growth
EPS Next Y-22.33%
EPS Next 2Y-8.48%
EPS Next 3Y2.64%
EPS Next 5YN/A
Revenue Next Year48.25%
Revenue Next 2Y136.46%
Revenue Next 3Y138.58%
Revenue Next 5Y117.81%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- NYXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year NYXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.48%
EPS Next 3Y2.64%
5. Dividend
5.1 Amount
- No dividends for NYXH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EBR:NYXH (1/21/2026, 7:00:00 PM)
4.1
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-12 2026-01-12/amc
Earnings (Next)05-12 2026-05-12
Inst Owners17.27%
Inst Owner ChangeN/A
Ins Owners19.98%
Ins Owner ChangeN/A
Market Cap176.42M
Revenue(TTM)5.64M
Net Income(TTM)-83.57M
Analysts81.43
Price Target9.56 (133.17%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.07%
Min EPS beat(2)-5.02%
Max EPS beat(2)5.16%
EPS beat(4)2
Avg EPS beat(4)-4.98%
Min EPS beat(4)-22.16%
Max EPS beat(4)5.16%
EPS beat(8)5
Avg EPS beat(8)-2.41%
EPS beat(12)6
Avg EPS beat(12)-9.44%
EPS beat(16)9
Avg EPS beat(16)-3.71%
Revenue beat(2)0
Avg Revenue beat(2)-1.35%
Min Revenue beat(2)-1.4%
Max Revenue beat(2)-1.3%
Revenue beat(4)0
Avg Revenue beat(4)-19.45%
Min Revenue beat(4)-38.43%
Max Revenue beat(4)-1.3%
Revenue beat(8)1
Avg Revenue beat(8)-18.47%
Revenue beat(12)1
Avg Revenue beat(12)-25.3%
Revenue beat(16)1
Avg Revenue beat(16)-32.33%
PT rev (1m)-5.06%
PT rev (3m)-26.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.46%
EPS NY rev (1m)0.04%
EPS NY rev (3m)-3.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.2%
Revenue NY rev (1m)-2.22%
Revenue NY rev (3m)-5.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 31.29 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.46 | ||
| P/tB | 208.54 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.24
EYN/A
EPS(NY)-2.12
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.57
OCFYN/A
SpS0.13
BVpS1.18
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -89.29% | ||
| ROE | -164.01% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.36% | ||
| FCFM | N/A |
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 32.99% | ||
| Cap/Sales | 21.88% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.41 | ||
| Altman-Z | -4.21 |
F-Score3
WACC7.43%
ROIC/WACCN/A
Cap/Depr(3y)64.88%
Cap/Depr(5y)74.74%
Cap/Sales(3y)37.33%
Cap/Sales(5y)219.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.02%
EPS Next Y-22.33%
EPS Next 2Y-8.48%
EPS Next 3Y2.64%
EPS Next 5YN/A
Revenue 1Y (TTM)10.96%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%55.77%
Revenue Next Year48.25%
Revenue Next 2Y136.46%
Revenue Next 3Y138.58%
Revenue Next 5Y117.81%
EBIT growth 1Y-59.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-47.24%
EBIT Next 3Y-14.81%
EBIT Next 5Y11.04%
FCF growth 1Y-49.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.83%
OCF growth 3YN/A
OCF growth 5YN/A
NYXOAH SA / NYXH.BR FAQ
What is the fundamental rating for NYXH stock?
ChartMill assigns a fundamental rating of 2 / 10 to NYXH.BR.
Can you provide the valuation status for NYXOAH SA?
ChartMill assigns a valuation rating of 0 / 10 to NYXOAH SA (NYXH.BR). This can be considered as Overvalued.
Can you provide the profitability details for NYXOAH SA?
NYXOAH SA (NYXH.BR) has a profitability rating of 1 / 10.
What is the financial health of NYXOAH SA (NYXH.BR) stock?
The financial health rating of NYXOAH SA (NYXH.BR) is 2 / 10.
Can you provide the expected EPS growth for NYXH stock?
The Earnings per Share (EPS) of NYXOAH SA (NYXH.BR) is expected to decline by -22.33% in the next year.